HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

AuthorsLecia V Sequist, Zofia Piotrowska, Matthew J Niederst, Rebecca S Heist, Subba Digumarthy, Alice T Shaw, Jeffrey A Engelman
JournalJAMA oncology (JAMA Oncol) Vol. 2 Issue 4 Pg. 541-3 (Apr 2016) ISSN: 2374-2445 [Electronic] United States
PMID26720284 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Piperazines
  • Pyrimidines
  • osimertinib
  • rociletinib
Topics
  • Acrylamides (therapeutic use)
  • Aniline Compounds
  • Antineoplastic Agents (therapeutic use)
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Humans
  • Lung Neoplasms (drug therapy)
  • Male
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: